Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE We recruited 50 out of 350 MTC plasma samples (27 female and 23 male) which were selected based on RET mutation in exon 11 (25 RET-positive and 25 RET-negative), with a mean ± SD age of 37.04 ± 1.74 years. 31297834 2020
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE There are few studies on the mutations and epigenetic changes of RET gene in Iranian patients with MTC. 30873628 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE In this study, we collected clinical and molecular data from 554 patients with surgically confirmed MTC from 176 families with MEN2 in 18 different Brazilian centers to compare the type and prevalence of RET mutations with those from other countries. 30763276 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE Thirty-three percent were diagnosed with benign nodules (n=151), 36% with papillary or follicular thyroid cancer (n=168), 27% with Graves' disease (n=124), 3% with medullary thyroid cancer (n=14), and 1.5% underwent prophylactic thyroidectomy for MEN2a (n=7). 30902456 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE Structural and metastatic recurrence is common in patients with germline RET mutations, and MTC and can occur 20 years after initial treatment, however survival remains high. 31549322 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE Through MLPA we have found evidence of CNA in the RET gene in MTC samples and MTC cell lines. 31288802 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 Biomarker disease BEFREE Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations. 31510104 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE p.Ser891Ala RET gene mutations in medullary thyroid cancer: Phenotypical and genealogical characterization of 28 apparently unrelated kindreds and founder effect uncovering in Northern Italy. 30927507 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE We report here that RET(C618F), a mutation identified in MTC patients, displays moderately high basal activity and requires the ligand for its full activation. 30884088 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE The heritable MTC results from a germline mutation in the rearranged during transfection (RET) proto-oncogene and is included into the multiple endocrine neoplasia 2 (MEN2), being associated with other endocrine abnormalities and clinical features. 31658309 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE RET mutation was related to cervical lymph node metastasis in patients with MTC, especially the mutation in Exon 11&13. 31494787 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 AlteredExpression disease BEFREE MEN1 is characterized by the occurrence of parathyroid, enteropancreatic, and pituitary tumors; MEN2A is characterized by medullary thyroid carcinoma and pheochromocytoma, and MEN4 is characterized by a pathological spectrum similar to that of MEN1 in association with tumors of the adrenal, kidney, and reproductive organs. 30641519 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 Biomarker disease BEFREE Medical records and laboratory reports of carriers were reviewed for signs of MEN2A at latest follow-up (medullary thyroid carcinoma, primary hyperparathyroidism, pheochromocytoma, cutaneous lichen amyloidosis, or Hirschsprung's disease). 30644554 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE Since early surgery with complete resection of tumor mostly determines the likelihood of attaining cure for MTC, the broader use of RET genetic screening has dramatically changed the prognostic of gene carriers in hereditary MTC. 31252403 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE To analyze the long-term outcomes in MEN2 and compare MTC aggressiveness in three defined RET mutation-risk categories: moderate risk (MOD), high risk (H), and highest risk (HST). 31145454 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 Biomarker disease BEFREE Meta-analysis of RET SNPs including our cohort identified increased risk association of all four RET SNPs with MTC. 31408923 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 AlteredExpression disease BEFREE In conclusion, these data indicate that an unbalanced cofilin expression, induced by oncogenic RET, contributes to promote MTC invasiveness and growth, suggesting the possibility of targeting cofilin pathway for more effective treatment of MTC. 31352037 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE MTC can be sporadic (75%) or familial (25%) and the 2 forms are distinguished by RET mutations analysis. 30717909 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 AlteredExpression disease BEFREE Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors. 29549836 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 Biomarker disease BEFREE In the era of genetic testing, RET status significantly influences disease-specific survival in MTC. 29484475 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE We describe a patient with homozygous RET K666N mutation with MTC and bilateral pheochromocytoma (PHEO). 29408964 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 Biomarker disease BEFREE MEN2B is mainly characterized by the early occurrence of MTC, which led the American Thyroid Association to recommend preventive thyroidectomy before the age of 1 year. 28698189 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 GeneticVariation disease BEFREE In the present study, we investigated whether the oncogenic RET mutants RET2A (C634R) and RET2B (M918T) were regulated by LRIG1, and the possible effects of LRIG1 expression in thyroid cancer were investigated in three different clinical cohorts and in a RET2B-driven mouse model of MTC. 29436694 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 Biomarker disease BEFREE Patients who died because of MTC had a median age of 61 years (range 21-84) and were at stages III-IV in all cases; deaths occurred in 18% of sporadic MTC, 6% of MEN2a and 66.7% of MEN2b patients. 29134313 2018
Entrez Id: 5979
Gene Symbol: RET
RET
0.700 Biomarker disease BEFREE In first-in-human testing, BLU-667 significantly inhibited RET signaling and induced durable clinical responses in patients with <i>RET</i>-altered NSCLC and MTC without notable off-target toxicity, providing clinical validation for selective RET targeting.<b>Significance:</b> Patients with <i>RET</i>-driven cancers derive limited benefit from available MKIs. 29657135 2018